14 research outputs found

    Intravenous Iron Carboxymaltose as a Potential Therapeutic in Anemia of Inflammation

    No full text
    <div><p>Intravenous iron supplementation is an effective therapy in iron deficiency anemia (IDA), but controversial in anemia of inflammation (AI). Unbound iron can be used by bacteria and viruses for their replication and enhance the inflammatory response. Nowadays available high molecular weight iron complexes for intravenous iron substitution, such as ferric carboxymaltose, might be useful in AI, as these pharmaceuticals deliver low doses of free iron over a prolonged period of time. We tested the effects of intravenous iron carboxymaltose in murine AI: Wild-type mice were exposed to the heat-killed <i>Brucella abortus</i> (BA) model and treated with or without high molecular weight intravenous iron. 4h after BA injection followed by 2h after intravenous iron treatment, inflammatory cytokines were upregulated by BA, but not enhanced by iron treatment. In long term experiments, mice were fed a regular or an iron deficient diet and then treated with intravenous iron or saline 14 days after BA injection. Iron treatment in mice with BA-induced AI was effective 24h after iron administration. In contrast, mice with IDA (on iron deficiency diet) prior to BA-IA required 7d to recover from AI. In these experiments, inflammatory markers were not further induced in iron-treated compared to vehicle-treated BA-injected mice. These results demonstrate that intravenous iron supplementation effectively treated the murine BA-induced AI without further enhancement of the inflammatory response. Studies in humans have to reveal treatment options for AI in patients.</p></div

    Serum cytokine levels measured after BA and intravenous iron administration.

    No full text
    <p>(<b>A</b>) Serum IL-6 protein levels were determined in C57BL/6 mice 4h after intraperitoneal BA or PBS administration followed by intravenous iron or PBS injection for an additional 2h (n = 3, 2-way ANOVA P = 0.003; *P = 0.04: PBS/PBS vs BA/PBS; *P = 0.04: PBS/iron vs BA/PBS). <b>(B)</b> Serum TNF-α levels (n = 3, 2-way ANOVA P = 0.03; **P = 0.009: PBS/PBS vs BA/PBS; *P = 0.03: PBS/PBS vs BA/iron; **P = 0.009: PBS/iron vs BA/PBS; *P = 0.03: PBS/iron vs BA/iron).</p

    Hepatic mRNA levels of pSTAT3, MCP-1, SOD2 and activin B in the liver of WT mice after BA and intravenous iron injection.

    No full text
    <p><b>(A)</b> Phosphorylated STAT3 levels compared to α-tubulin in the liver of C57BL/6 mice 4h after intraperitoneal BA or PBS administration followed by intravenous iron or PBS treatment for an additional 2h. <b>(B)</b> Hepatic MCP-1 mRNA levels were determined in WT mice after intraperitoneal BA or PBS administration followed by intravenous iron or PBS injection for an additional 2h (n = 3, 2-way ANOVA P<0,0001; **P = 0.007: PBS/PBS vs BA/PBS; *P = 0.02: PBS/PBS vs BA/iron; **P = 0.007: PBS/iron vs BA/PBS); (*P = 0.02: PBS/iron vs BA/iron; **P = 0.008: BA/PBS vs BA/iron; not shown in the graph). <b>(C)</b> Hepatic SOD2 mRNA levels in WT mice 4h after intraperitoneal BA or PBS administration followed by intravenous iron or PBS treatment for an additional 2h (n = 3, 2-way ANOVA P = 0.0002; **P = 0.004: PBS/PBS vs BA/PBS; **P = 0.004: PBS/PBS vs BA/iron); (**P = 0.006: PBS/iron vs BA/PBS; **P = 0.007: PBS/iron vs BA/iron, not shown in graph). <b>(D)</b> Hepatic activin B mRNA levels in WT mice 4h after intraperitoneal BA or PBS administration followed by intravenous iron or PBS injection for an additional 2h (n = 3, 2-way ANOVA P<0,0001; **P = 0.009: PBS/PBS vs BA/PBS; ***P = 0.0002: PBS/PBS vs BA/iron); (**P = 0.009: PBS/iron vs BA/PBS; ***P = 0.0003: PBS/iron vs BA/iron, not shown in graph).</p

    Hepcidin response to iron treatment depends on the diets.

    No full text
    <p>WT mice were challenged with or without intraperitoneal BA injection and 14d later treated with or without intravenous iron. <b>(A)</b> Hepatic hepcidin mRNA levels 24h after iron treatment in mice fed a regular iron diet (black bars) or an iron deficient diet (white bars) (iron deficient diet: n = 4, 2-way ANOVA P = 0.006; *P = 0.01: PBS/PBS vs BA/iron; ***P = 0.0002: BA/PBS vs BA/iron). <b>(B)</b> Hepcidin mRNA levels 7d after the iron treatment in mice as in (A) (iron deficient diet: n = 4, 2-way ANOVA P = 0.0007; *p = 0.02: PBS/PBS vs BA/PBS; **P = 0.001: BA/PBS vs BA/iron). <b>(C)</b> Liver iron content (LIC) was determined in C57BL/6 mice fed a regular or iron deficient diet. LIC 14d after BA and 24h after intravenous iron administration are shown (regular diet: n = 3–4, 2-way ANOVA P = 0.002; **P = 0.008: PBS/PBS vs BA/PBS, iron deficient diet: n = 4, 2-way ANOVA, P < 0.0001; **P = 0.005: PBS/PBS vs BA/iron; **P = 0.004: BA/PBS vs BA/iron). <b>(D)</b> LIC 14d after BA and 7d after iron treatment in mice fed a regular or an iron deficient diet (iron deficient diet: n = 4, 2-way ANOVA P = 0.0002; *P = 0.01: PBS/PBS vs BA/iron; *P = 0.01: BA/PBS vs BA/iron).</p

    Additional file 1: of Deficiency of the BMP Type I receptor ALK3 partly protects mice from anemia of inflammation

    No full text
    Experimental design. (a) Mice were fed an iron deficient diet since weaning and throughout the experiment. At the age of 12 weeks, female Alk3fl/fl; Alb-Cre and Alk3fl/fl mice were intraperitoneally injected with 5 × 108 particles/mouse of heat-killed Brucella abortus (BA) or saline. Two weeks later blood and organs were collected. (b) 12 week old Alk3fl/fl; Alb-Cre and Alk3fl/fl female mice fed a regular diet were intravenously inoculated with 1 × 106 colony forming units (CFUs) of Staphylococcus aureus. Twenty-four hours later blood and organs were collected. (TIFF 164 kb

    Additional file 5: of Deficiency of the BMP Type I receptor ALK3 partly protects mice from anemia of inflammation

    No full text
    Liver and spleen iron content from Alk3fl/fl and Alk3fl/fl; Alb-Cre mice 14 days after BA challenge. (a) Liver iron content in Alk3fl/fl and Alk3fl/fl; Alb-Cre mice 14 days after heat-killed Brucella abortus (BA) injection (*P = 0.04: Alk3fl/fl; Alb-Cre injected with saline [n = 4] vs Alk3fl/fl; Alb-Cre injected with BA [n = 6]). (b) Spleen iron content from Alk3fl/fl and Alk3fl/fl; Alb-Cre mice 14 days after heat-killed Brucella abortus (BA) injection. (TIFF 82 kb

    Intravenous iron treated BA-induced anemia in mice.

    No full text
    <p>WT mice were challenged with intraperitoneal BA injection and 14d later treated with intravenous iron. <b>(A)</b> Hemoglobin levels 24h after the iron treatment in mice fed a regular (black bars) or iron deficient (white bars) diet (regular diet: n = 3, 2-way ANOVA P < 0,0001; ***P = 0.0006: PBS/PBS vs BA/PBS; *P = 0.02: BA/PBS vs BA/iron). <b>(B)</b> Hemoglobin levels 7d after the intravenous iron treatment as in (A) (iron deficient diet: n = 4, 2-way ANOVA P = 0.002; ***P = 0.0007: PBS/PBS vs BA/PBS; **P = 0.003: BA/PBS vs BA/iron). <b>(C)</b> Serum iron levels 24h after intravenous iron treatment in mice on a regular or iron deficient diet (iron deficient diet: n = 4, 2-way ANOVA P = 0.007; **P = 0.006: PBS/PBS vs BA/PBS; **P = 0.006: BA/PBS vs BA/iron). <b>(D)</b> Serum iron levels 7d after intravenous iron treatment as in (C).</p

    Induction of hepatic hepcidin mRNA levels and serum iron levels after intraperitoneal injection of BA and/or intravenous iron carboxymaltose administration.

    No full text
    <p><b>(A)</b> Hepatic hepcidin mRNA levels were determined by quantitative RT-PCR in C57BL/6 mice 4h after intraperitoneal BA or PBS administration followed by intravenous iron or PBS treatment for an additional 2h (values represent mean±SD, n = 3, 2-way ANOVA, P = 0.002; **P = 0.004: PBS/PBS vs BA/PBS, and **P = 0.002: PBS/PBS vs BA/iron). <b>(B)</b> Serum iron levels were measured (values represent mean±SD, n = 3, 2-way ANOVA, P = 0.0008; *P = 0.02: PBS/PBS vs PBS/iron, *P = 0.01: PBS/PBS vs BA/PBS, *P = 0.04: PBS/PBS vs BA/iron, and *P = 0.03: BA/PBS vs BA/iron).</p

    Reticulocyte production index (RPI) in BA-challenged mice fed a regular or an iron deficient diet and treated with intravenous iron or PBS.

    No full text
    <p>WT mice were fed a regular or iron deficient diet and injected with BA intraperitoneally followed 14d later by intravenous iron or PBS treatment. <b>(A)</b> Reticulocyte production Index (RPI = Retic%xHb/14.46, with 14.46g/dL as the mean baseline hemoglobin (Hb) level of healthy WT mice) 24h after iron or PBS treatment (2-way ANOVA P = 0.01, regular diet: n = 3, *P = 0.03: PBS/PBS vs BA/PBS; iron deficient diet: n = 3; *P = 0.02: PBS/PBS vs BA/iron). <b>(B)</b> Reticulocyte production 7d after iron or PBS treatment (iron deficient diet: n = 3–4, 2-way ANOVA P = 0.008; *P = 0.04: PBS/PBS vs BA/iron).</p

    Philippe Lachaud, architecte et urbaniste (1935-2012)

    No full text
    Liver and spleen iron content from Alk3fl/fl and Alk3fl/fl; Alb-Cre mice 14 days after BA challenge. (a) Liver iron content in Alk3fl/fl and Alk3fl/fl; Alb-Cre mice 14 days after heat-killed Brucella abortus (BA) injection (*P = 0.04: Alk3fl/fl; Alb-Cre injected with saline [n = 4] vs Alk3fl/fl; Alb-Cre injected with BA [n = 6]). (b) Spleen iron content from Alk3fl/fl and Alk3fl/fl; Alb-Cre mice 14 days after heat-killed Brucella abortus (BA) injection. (TIFF 82 kb
    corecore